US FDA clears Roche's Elecsys blood test for potential heart attack
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
The U.S. FDA approved Roche Holding Ltd.'s Elecsys troponin T blood test to diagnose patients with a suspected heart attack.
This makes Roche the first in-vitro diagnostics company in the U.S. to provide the next generation blood test.
